Skip to main content
Premium Trial:

Request an Annual Quote

Serologicals Shutters Canadian Facility in Plant Consolidation Effort

NEW YORK, Jan. 9 (GenomeWeb News) - As part of its ongoing consolidation effort, Serologicals closed a Canadian plant and will not open another facility as planned in 2006 in Kansas, the company said last week.


A facility in Toronto will be closed and all cell culture product manufacturing will move to a facility in Kankakee, Ill., during the first half of 2006, the company said.


During the past six months, Serologicals has expanded the Kankakee facility's production capacity by more than 50 percent, making it unnecessary to open the facility in Lawrence.


Both the Toronto and Lawrence, Kan. facilities will be prepared for sale and written down to net realizable value and will be included in the company's fourth quarter 2005 results.


As GenomeWeb News reported in July 2005, Serologicals is restructuring to reduce research costs by $3 million to $3.5 million a year.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.